Ligand Pharmaceuticals (NASDAQ:LGND) Upgraded to “Hold” at StockNews.com
StockNews.com upgraded shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning. Other equities research analysts have also issued research reports about the stock. Royal Bank of Canada raised their target price on shares of Ligand Pharmaceuticals from $141.00 […]
StockNews.com upgraded shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning. Other equities research analysts have also issued research reports about the stock. Royal Bank of Canada raised their target price on shares of Ligand Pharmaceuticals from $141.00 […]
